Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature

被引:13
|
作者
Reynaert, Hendrik [1 ,2 ]
Colle, Isabelle [3 ,4 ]
机构
[1] UZBrussel, Dept Gastroenterol Hepatol, Laarbeeklaan 101, B-1090 Brussels, Belgium
[2] Vrije Univ Brussel, Liver Cell Biol Lab, Laarbeeklaan 103, B-1090 Brussels, Belgium
[3] ASZ Aalst, Dept Gastroenterol Hepatol, Merestr 80, B-9300 Aalst, Belgium
[4] Univ Ghent, Dept Gastroenterol Hepatol, Pintelaan, B-9000 Ghent, Belgium
关键词
hepatocellular carcinoma; octreotide; somatostatin; somatostatin analogues; somatostatin receptor; LONG-ACTING OCTREOTIDE; RECEPTOR SUBTYPES; PLUS OCTREOTIDE; PLACEBO; MULTICENTER; EXPRESSION; TUMOR; PROLIFERATION; PASIREOTIDE; SORAFENIB;
D O I
10.3390/ijms20194811
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocellular carcinoma, one of the most dreaded complications of cirrhosis, is a frequent cancer with high mortality. Early primary liver cancer can be treated by surgery or ablation techniques, but advanced hepatocellular carcinoma remains a challenge for clinicians. Most of these patients have underlying cirrhosis, which complicates or even precludes treatment. Therefore, efficacious treatments without major side effects are welcomed. Initial results of treatment of advanced hepatocellular carcinoma with somatostatin analogues were promising, but subsequent trials have resulted in conflicting outcomes. This might be explained by different patient populations, differences in dosage and type of treatment and differences in somatostatin receptor expression in the tumor or surrounding tissue. It has been shown that the expression of somatostatin receptors in the tumor might be of importance to select patients who could benefit from treatment with somatostatin analogues. Moreover, somatostatin receptor expression in hepatocellular carcinoma has been shown to correlate with recurrence, prognosis, and survival. In this review, we will summarize the available data on treatment of primary liver cancer with somatostatin analogues and analyze the current knowledge of somatostatin receptor expression in hepatocellular carcinoma and its possible clinical impact.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Treatment of advanced hepatocellular carcinoma
    Forner, Alejandro
    Rodriguez De Lope, Carlos
    Reig, Maria
    Bruix, Jordi
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2010, 33 (06): : 461 - 468
  • [22] TREATMENT OF NONRESECTABLE HEPATOCELLULAR-CARCINOMA - REVIEW OF THE LITERATURE AND METAANALYSIS
    MALAGUARNERA, M
    TROVATO, G
    RESTUCCIA, S
    GIUGNO, I
    FRANZE, CMC
    RECEPUTO, G
    SICILIANO, R
    MOTTA, M
    TROVATO, BA
    ADVANCES IN THERAPY, 1994, 11 (06) : 303 - 319
  • [23] LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW
    Croitoru, A.
    Dinu, I
    Herlea, V
    Becheanu, G.
    Grasu, M.
    Lupescu, I
    Dima, S. O.
    Buica, F.
    Dumitrascu, T.
    Lungulescu, C.
    Croitoru, V. M.
    Tanase, A.
    Negru, S. M.
    Gramaticu, I. M.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2019, 15 (03) : 390 - 397
  • [24] Somatostatin and somatostatin analogues in medullary thyroid carcinoma
    OByrne, KJ
    OHare, N
    Sweeney, E
    Freyne, PJ
    Cullen, MJ
    NUCLEAR MEDICINE COMMUNICATIONS, 1996, 17 (09) : 810 - 816
  • [25] Dosimetry for treatment with radiolabelled somatostatin analogues. A review
    Cremonesi, M.
    Botta, F.
    Di Dia, A.
    Ferrari, M.
    Bodei, L.
    De Cicco, C.
    Rossi, A.
    Bartolomei, M.
    Mei, R.
    Severi, S.
    Salvatori, M.
    Pedroli, G.
    Paganelli, G.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (01): : 37 - 51
  • [26] Anti-angiogenesis effect of Somatostatin/analogues: case study - hepatocellular carcinoma
    Gheorghiu, M
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152
  • [27] Treatment of neuroendocrine GEP tumours with somatostatin analogues - A review
    Arnold, R
    Simon, B
    Wied, M
    DIGESTION, 2000, 62 : 84 - 91
  • [28] Case Report and Literature Review of Multi-drugs Synergy and Targeted Comprehensive Treatment in Advanced Hepatocellular Carcinoma
    Lu, Guanhua
    Ou, Limin
    Cao, Mingrong
    Hu, Min
    CURRENT CANCER DRUG TARGETS, 2024, 24 (03) : 368 - 374
  • [29] Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
    Emma D. Deeks
    Targeted Oncology, 2019, 14 : 107 - 113
  • [30] Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
    Deeks, Emma D.
    TARGETED ONCOLOGY, 2019, 14 (01) : 107 - 113